Biolojic Design has announced the launch of a clinical trial of its first-ever computationally designed antibody, AU-007, to treat patients with solid tumours.
A monoclonal antibody, AU-007 uses interleukin-2 (IL-2) of the body to destroy solid cancer tumours.
The company transferred the antibody to its spinoff, Aulos Bioscience, which is currently developing it.
Aulos is presently carrying out clinical trials in Australia with patient enrolment underway to report interim results later this year.
The antibody, which is being developed with $40m proceeds from Series A financing round, will be advanced from the preclinical stage through clinical proof-of-concept by Aulos that was established by Biolojic and life sciences venture capital firm Apple Tree Partners (ATP).
According to preclinical findings, AU-007 showed substantial tumour growth inhibition.
Complete elimination of tumour was observed in ten out of 19 mice treated with the antibody in combination with PD-1 or PD-L1 checkpoint inhibitors in a murine model of cancer.
Biolojic Design founder and CEO Yanay Ofran said: “Unlike the antibodies made by conventional antibody technologies, the promise of our approach is creating smart antibodies — a sort of nanorobot that, like naturally occurring proteins, is able to adapt to changing situations.
“The antibody that is entering the clinic now was designed based on our understanding of the IL-2 pathway.”
The company leverages its artificial intelligence (AI) platform for designing antibodies with new abilities to treat disease.
Its preclinical portfolio included unique therapies developed using the AI platform.
Currently, Biolojic has collaborations in place with Nektar Therapeutics and Eli Lilly to develop antibodies against autoimmune diseases and diabetes, respectively.